Cargando…

P1681: FXI LEVELS AS INDEPENDENT RISK FACTOR FOR THROMBOSIS/OBSTETRIC EVENTS IN PATIENTS WITH ANTIPHOSPHOLIPID ANTIBODIES

Detalles Bibliográficos
Autores principales:	De La Morena-Barrio, M. E., Pagan, J., Miñano, A., Roldan, V., Lopez-Arribas, A., Lozano, J., Hernandez-Vidal, M. J., de la Morena-Barrio, I., Vicente, V., Lozano, M. L., Herranz, M. T., Corral, J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430803/ http://dx.doi.org/10.1097/01.HS9.0000849580.50369.0b

Ejemplares similares

Factor XI in Carriers of Antiphospholipid Antibodies: Elevated Levels Associated with Symptomatic Thrombotic Cases, While Low Levels Linked to Asymptomatic Cases
por: Pagán-Escribano, Javier, et al.
Publicado: (2023)

Anticoagulant therapy in patients with congenital FXI deficiency
por: Bravo-Pérez, Carlos, et al.
Publicado: (2021)

Incidence and features of thrombosis in children with inherited antithrombin deficiency
por: de la Morena-Barrio, Belén, et al.
Publicado: (2019)

Prognostic value of thrombin generation parameters in hospitalized COVID-19 patients
por: de la Morena-Barrio, María Eugenia, et al.
Publicado: (2021)

Commentary on Acquired Factor XI Deficiency during SARS-CoV-2 Infection: Not Only Thrombosis
por: de la Morena-Barrio, Maria E.
Publicado: (2020)

Model‐dependent contributions of FXII and FXI to venous thrombosis in mice
por: Grover, Steven P., et al.
Publicado: (2020)

Usefulness and Limitations of Multiple Ligation-Dependent Probe Amplification in Antithrombin Deficiency
por: Cifuentes, Rosa, et al.
Publicado: (2023)

Transient desialylation in combination with a novel antithrombin deficiency causing a severe and recurrent thrombosis despite anticoagulation therapy
por: Revilla, Nuria, et al.
Publicado: (2017)

ALG12‐CDG: An unusual patient without intellectual disability and facial dysmorphism, and with a novel variant
por: de la Morena‐Barrio, María Eugenia, et al.
Publicado: (2020)

Analysis of 272 Genetic Variants in the Upgraded Interactive FXI Web Database Reveals New Insights into FXI Deficiency
por: Harris, Victoria A., et al.
Publicado: (2021)

Association of FXI activity with thrombo-inflammation, extracellular matrix, lipid metabolism and apoptosis in venous thrombosis
por: Pallares Robles, Alejandro, et al.
Publicado: (2022)

Full-length antithrombin frameshift variant with aberrant C-terminus causes endoplasmic reticulum retention with a dominant-negative effect
por: Bravo-Pérez, Carlos, et al.
Publicado: (2022)

Recurrent mutations in a SERPINC1 hotspot associate with venous thrombosis without apparent antithrombin deficiency
por: Zeng, Wei, et al.
Publicado: (2017)

Correction: Recurrent mutations in a SERPINC1 hotspot associate with venous thrombosis without apparent antithrombin deficiency
por: Zeng, Wei, et al.
Publicado: (2018)

Functional, biochemical, molecular and clinical characterization of antithrombin c.1157T>C (p.Ile386Thr), a recurrent Polish variant with a founder effect
por: Weronska, Anna, et al.
Publicado: (2023)

Identification of Regulatory Mutations in SERPINC1 Affecting Vitamin D Response Elements Associated with Antithrombin Deficiency
por: Toderici, Mara, et al.
Publicado: (2016)

Correction: Identification of Regulatory Mutations in SERPINC1 Affecting Vitamin D Response Elements Associated with Antithrombin Deficiency
por: Toderici, Mara, et al.
Publicado: (2016)

Two SERPINC1 variants affecting N-glycosylation of Asn224 cause severe thrombophilia not detected by functional assays
por: de la Morena-Barrio, Maria Eugenia, et al.
Publicado: (2022)

1681P First results of the COCO study: COVID-19 outcomes in patients with cancer
por: Seguí, E., et al.
Publicado: (2020)

Factor XII in PMM2-CDG patients: role of N-glycosylation in the secretion and function of the first element of the contact pathway
por: López-Gálvez, Raquel, et al.
Publicado: (2020)

PK/PD modeling of FXI antisense oligonucleotides to bridge the dose‐FXI activity relation from healthy volunteers to end‐stage renal disease patients
por: Willmann, Stefan, et al.
Publicado: (2021)

BJTJ-1837, a novel FXI activation-blocking antibody
por: He, Xugang, et al.
Publicado: (2023)

Long-Read Sequencing Identifies the First Retrotransposon Insertion and Resolves Structural Variants Causing Antithrombin Deficiency
por: de la Morena-Barrio, Belén, et al.
Publicado: (2022)

Does Adjusted Global Antiphospholipid Syndrome Score (aGAPSS) Predict the Obstetric Outcome in Antiphospholipid Antibody Carriers? A Single-Center Study
por: Del Barrio-Longarela, Sara, et al.
Publicado: (2021)

Obstetric antiphospholipid syndrome
por: Antovic, Aleksandra, et al.
Publicado: (2018)

Improvement of large copy number variant detection by whole genome nanopore sequencing
por: Cuenca-Guardiola, Javier, et al.
Publicado: (2022)

Antiphospholipid antibodies and thrombosis: pathogenesis of antiphospholipid syndrome
por: Koike, T
Publicado: (2003)

“Familial Multiple Coagulation Factor Deficiencies of FXI and FXII in an Asymptomatic Saudi Woman”
por: Al-Ansari, Rehab Y., et al.
Publicado: (2023)

GPI-anchor and GPI-anchored protein expression in PMM2-CDG patients
por: de la Morena-Barrio, Maria E, et al.
Publicado: (2013)

Obstetrical Antiphospholipid Syndrome: From the Pathogenesis to the Clinical and Therapeutic Implications
por: Marchetti, T., et al.
Publicado: (2013)

Non-Criteria Obstetric Antiphospholipid Syndrome: How Different Is from Sidney Criteria? A Single-Center Study
por: Martínez-Taboada, Víctor M., et al.
Publicado: (2022)

1681. Assessment of the Impact of Infectious Events in a Cohort of Pediatric Leukemia Patients in the Dominican Republic
por: Burns, Julianne E, et al.
Publicado: (2019)

P1681: RACIAL DIFFERENCES IN DETERMINANTS OF TREATMENT DECISION-MAKING AMONG PATIENTS WITH MULTIPLE MYELOMA
por: Dwyer, Lisa, et al.
Publicado: (2023)

Biochemical and cellular consequences of the antithrombin p.Met1? mutation identified in a severe thrombophilic family
por: Navarro-Fernández, José, et al.
Publicado: (2018)

Phase 2 Study of the Factor XI Antisense Inhibitor IONIS-FXI(Rx) in Patients With ESRD
por: Walsh, Michael, et al.
Publicado: (2021)

Obstetric antiphospholipid syndrome: Number 6 - June 2021
por: Barros, Venina Isabel Poço Viana Leme de, et al.
Publicado: (2021)

Seronegative Obstetric Antiphospholipid Syndrome Finally Treated Successfully
por: Alghanim, Khawla K, et al.
Publicado: (2022)

Detection and annotation of transposable element insertions and deletions on the human genome using nanopore sequencing
por: Cuenca-Guardiola, Javier, et al.
Publicado: (2023)

Differences in Antiphospholipid Antibody Profile between Patients with Obstetric and Thrombotic Antiphospholipid Syndrome
por: Anunciación-Llunell, Ariadna, et al.
Publicado: (2022)

The FXII c.-4T>C Polymorphism as a Disease Modifier in Patients With Hereditary Angioedema Due to the FXII p.Thr328Lys Variant
por: Corvillo, Fernando, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_4f859v4b2cuu4putike315k6of